What to Know Before Choosing JUVÉDERM VOLLURE XC for Smile Lines

JUVÉDERM VOLLURE XC is a temporary hyaluronic acid filler approved for injection into the mid-to-deep dermis to correct moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over 21. It may suit someone seeking temporary smoothing of pronounced smile lines, but “up to 18 months” is a maximum-qualified claim—not a promise of typical longevity. Before treatment, confirm that the proposed area matches the approved indication and discuss contraindications, expected reactions, costs, follow-up, and vascular-emergency readiness with a properly licensed practitioner. FDA Summary of Safety and Effectiveness Data

The short answer: what VOLLURE filler is approved to do

VOLLURE XC at a glance

• Product type: Temporary injectable dermal filler made from crosslinked hyaluronic acid
• Approved treatment: Moderate to severe facial wrinkles and folds, such as nasolabial folds
• Injection depth: Mid-to-deep dermis
• Approved population: Adults over 21
• Documented formulation: 17.5 mg/mL hyaluronic acid and 0.3% lidocaine
• Provider: A licensed physician or other properly licensed practitioner

These details come from the product’s 2017 FDA approval record.

“Smile lines” is a broad consumer term. Approval does not mean the product is appropriate for every fold or every adult. Facial anatomy, treatment goals, health history, and the condition of the proposed injection site still require individual assessment.

VOLLURE XC is available through a licensed physician or other properly licensed practitioner. Ask who will perform the injection and confirm that the person is properly licensed to do so.

Approved use versus uses not established by this evidence

Products within the JUVÉDERM range have different indications. A claim attached to one formula or treatment area should not automatically be transferred to VOLLURE XC.

FDA-supported VOLLURE use	Uses not established for VOLLURE here
Correction of moderate to severe facial wrinkles and folds	Lip augmentation
Nasolabial-fold treatment	Cheek augmentation
Mid-to-deep dermal injection in the approved facial treatment area	Tear-trough or under-eye treatment
	Periorbital injection

The right-hand column does not establish that these uses are prohibited. It means the FDA-supported VOLLURE claims described here cannot be extended to those areas without separate, product-specific evidence. If a practitioner proposes a use outside the approved indication, ask them to identify it as off-label and explain the evidence and clinical rationale.

For example, an adult over 21 researching treatment for pronounced nasolabial folds is considering the approved anatomical indication, subject to clinical screening. Someone seeking lip enhancement is asking a different question and needs evidence about the exact product, formulation, injection area, and proposed technique.

This distinction also matters when discussing longevity and safety. General estimates for lip fillers do not establish how VOLLURE performs in the lips, and results from nasolabial-fold treatment cannot be assumed to apply around the eyes. Ask the practitioner to name the exact product and state whether the proposed treatment is within its approved indication.

How to interpret the 18-month and 96% claims

Two prominent manufacturer-reported figures require context:

Claim	Context
“Up to 18 months”	The manufacturer says results in smile lines can last up to 18 months with optimal treatment. “Up to” describes a possible maximum, not the typical, median, or guaranteed duration for an individual. The available public description does not define precisely what “optimal treatment” involved.
“96% improved at six months”	The manufacturer reports improvement in nasolabial folds for 96% of patients at the six-month assessment. This is an improvement measure at one assessment point; it does not by itself prove satisfaction, superiority to another filler, or continued correction through month 18.

Both figures appear on the official JUVÉDERM smile-lines product page. The public summary does not include the complete outcome tables needed to determine how many patients retained a particular degree of correction at every later assessment.

Several practical questions therefore remain unresolved:

• What is the typical or median duration of visible correction?
• What exactly counted as “optimal treatment”?
• When do most patients consider maintenance?
• How accurately can duration be predicted for one person?
• How did the degree of correction change between six and 18 months?

A responsible consultation should translate the headline into a range of possible outcomes without guaranteeing a duration. It should also define what “lasting” means. Some residual change, maintenance of a target correction, and the point at which a patient personally wants another treatment are not necessarily the same endpoint.

How VOLLURE was studied and administered

The pivotal evidence came from a randomized, double-blind, within-subject controlled study conducted at six investigational sites, with 123 treated participants. One nasolabial fold on each participant received VOLLURE XC, while the opposite fold received another FDA-approved crosslinked hyaluronic acid filler. This split-face design allowed each participant to serve as their own comparison. (FDA approval record.)

The six-month effectiveness assessment included a test of non-inferiority. In plain language, this asks whether VOLLURE performed no worse than the comparator by more than a prespecified margin. It does not support a claim that VOLLURE was superior to the unnamed comparator. (FDA approval record.)

Follow-up continued through 18 months after the last initial or touch-up treatment. Follow-up length should not be confused with proof that a typical participant retained a specified result for the full 18 months; the available FDA excerpt does not include complete durability outcome tables. (FDA approval record.)

In practice, a properly licensed practitioner may inject VOLLURE using a needle or cannula. The practitioner must understand the intended injection depth, relevant anatomy, and the process for responding to suspected vascular compromise. (FDA approval record and manufacturer safety information.)

Treatment volume also requires an individual plan. A maximum volume permitted in a clinical protocol is a study boundary—not a normal dose, recommended syringe quantity, or suitable amount for a particular person. Ask how the proposed volume relates to the severity of the folds, the intended degree of correction, and the plan for avoiding overcorrection.

Common reactions versus rare medical emergencies

Routine injection-site reactions and vascular complications belong in different risk tiers. Common does not mean inevitable, and rare does not mean unimportant.

Risk tier	Reported effects	What it means
Common local reactions	Swelling, tenderness, firmness, lumps or bumps, bruising, pain, redness, itching, and discoloration	Usually localized to the injection area; duration and effects on daily activities vary
Rare vascular complications	Skin necrosis, permanent scarring, damage to underlying facial structures, temporary or permanent vision impairment, blindness, or stroke	May follow accidental injection into a blood vessel and can be irreversible; suspected complications require immediate medical evaluation

The manufacturer characterized common reactions in the cited VOLLURE trial as mild or moderate and lasting 14 days or less. Its broader JUVÉDERM safety information says most commonly reported injection effects resolve within 30 days. These statements address different scopes and should not be converted into a guaranteed recovery schedule. Official manufacturer product and safety information

Reported potential outcomes of intravascular facial-filler injection include skin necrosis, permanent scarring, injury to underlying facial structures, impaired vision or blindness, and stroke. These risks make anatomical knowledge and a clear emergency process central to provider selection. (FDA approval record and manufacturer safety information.)

Seek immediate medical attention for unusual pain, a vision change, or skin becoming white, gray or blue near the injection site during or shortly after treatment. Sudden speech difficulty, facial drooping or limb weakness can be stroke signs and require emergency help. These are FDA warning signs for dermal fillers, not a VOLLURE-specific home-treatment protocol. Before treatment, obtain written instructions for urgent contact and escalation.

Post-market reports can identify possible adverse-event patterns, including events that are uncommon or emerge outside clinical trials. Because reporting is voluntary and may be incomplete, these reports cannot establish a complication rate. An event reported after treatment also does not by itself prove that VOLLURE caused it. (FDA approval record.)

Who should avoid or postpone treatment

Use the following as a consultation-screening checklist, not as a self-diagnosis or final eligibility decision. Tell the practitioner if any item applies:

• History of anaphylaxis
• Severe allergies or multiple severe allergies
• Allergy to lidocaine
• Allergy to Gram-positive bacterial proteins
• A previous allergic reaction to a hyaluronic acid filler
• Sores, pimples, rashes, hives, cysts, or infection at the planned injection site
• Pregnancy or breastfeeding
• Any current condition or previous filler reaction that may affect treatment planning

VOLLURE XC is contraindicated for people with severe allergies manifested by a history of anaphylaxis or with a history or presence of multiple severe allergies. Its labeling also identifies allergies to lidocaine and Gram-positive bacterial proteins as contraindications. (FDA approval record.)

The manufacturer advises against treatment following a previous allergic reaction to a hyaluronic acid filler. Treatment should be postponed when sores, pimples, rashes, hives, cysts, or infections are present at the planned injection site. The safety of JUVÉDERM products during pregnancy or breastfeeding has not been studied, so treatment should not be described as established safe in either situation. (Manufacturer safety information.)

Bring a complete allergy history, information about previous fillers and reactions, and details of current skin or health conditions to the consultation. The treating practitioner should determine whether to avoid, postpone, or modify the plan.

Questions to ask before consenting to VOLLURE

Save this checklist or bring it to the consultation.

Practitioner and product

• Are you properly licensed to perform this injection?
• Will you personally perform the entire treatment?
• What training and experience do you have with nasolabial-fold anatomy?
• Is the product genuine JUVÉDERM VOLLURE XC, and can I see the labeled packaging?
• Is my proposed treatment area within VOLLURE’s approved indication?
• If the plan is off-label, what product-specific evidence and clinical rationale support it?

Treatment plan and cost

• What volume do you propose, and why is that amount appropriate for my anatomy and goal?
• What degree of correction are you aiming for?
• What does the quoted total cost include?
• Are review appointments, touch-ups, or management of complications charged separately?
• What alternatives are appropriate for my concern, and what are their distinct trade-offs?

There is no supported universal price or “normal” number of syringes. Obtain a written quote tied to the exact product and proposed amount.

Results and follow-up

• How do you interpret “up to 18 months” for someone like me without promising that duration?
• What result should we use as the baseline after early swelling changes?
• When will you assess whether the initial treatment was adequate?
• What common reactions should I expect, and when do you want me to contact you?
• What is your approach if the result is asymmetric, overcorrected, or otherwise unsatisfactory?
• How does VOLLURE compare with appropriate alternatives for my specific concern?

Typical duration, maintenance timing, precise recovery, current cost, usual syringe quantity, and comparative performance remain unresolved by the evidence reviewed here. The reliability of reversal is also uncertain: do not assume that a hyaluronic acid filler can always be completely or predictably removed.

Emergency preparedness

• What complications are you prepared to recognize and manage?
• What is your process if you suspect injection into a blood vessel?
• How can I reach you urgently after leaving?
• Where would I be evaluated if escalation is needed?
• What written instructions will I receive?

A license is the starting point, not the entire evaluation. Experience with the intended anatomy, careful product identification, informed consent, follow-up access, and emergency readiness also matter.

VOLLURE XC has a defined role: temporary correction of moderate to severe facial folds such as nasolabial folds in adults over 21. A sound decision should not rest on the 18-month headline alone. Confirm the anatomical indication, disclose allergies and previous reactions, understand routine and serious risks, and ask for realistic expectations about volume, cost, maintenance, follow-up, and emergency response.

L·F Tokyo is an editorial publication, not a clinic or medical provider. Its coverage is informational, so personal eligibility and treatment decisions belong with a properly licensed practitioner.